Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Scale-down of the inactivated polio vaccine production process.

Thomassen YE, van 't Oever AG, Vinke M, Spiekstra A, Wijffels RH, van der Pol LA, Bakker WA.

Biotechnol Bioeng. 2013 May;110(5):1354-65. doi: 10.1002/bit.24798. Epub 2012 Dec 29.

PMID:
23192424
2.

Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV.

Bakker WA, Thomassen YE, van't Oever AG, Westdijk J, van Oijen MG, Sundermann LC, van't Veld P, Sleeman E, van Nimwegen FW, Hamidi A, Kersten GF, van den Heuvel N, Hendriks JT, van der Pol LA.

Vaccine. 2011 Sep 22;29(41):7188-96. doi: 10.1016/j.vaccine.2011.05.079. Epub 2011 Jun 7.

PMID:
21651934
3.

Multivariate data analysis on historical IPV production data for better process understanding and future improvements.

Thomassen YE, van Sprang EN, van der Pol LA, Bakker WA.

Biotechnol Bioeng. 2010 Sep 1;107(1):96-104. doi: 10.1002/bit.22788.

PMID:
20506395
4.

Industrial-scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier.

Montagnon BJ, Fanget B, Vincent-Falquet JC.

Rev Infect Dis. 1984 May-Jun;6 Suppl 2:S341-4.

PMID:
6740071
5.

PER.C6(®) cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine.

Sanders BP, Edo-Matas D, Custers JH, Koldijk MH, Klaren V, Turk M, Luitjens A, Bakker WA, Uytdehaag F, Goudsmit J, Lewis JA, Schuitemaker H.

Vaccine. 2013 Jan 21;31(5):850-6. doi: 10.1016/j.vaccine.2012.10.070. Epub 2012 Oct 30.

PMID:
23123018
6.

Decision analysis in planning for a polio outbreak in the United States.

Jenkins PC, Modlin JF.

Pediatrics. 2006 Aug;118(2):611-8.

PMID:
16882814
7.

New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines.

van Wezel AL, van Steenis G, Hannik CA, Cohen H.

Dev Biol Stand. 1978;41:159-68.

PMID:
223908
8.

CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.

Yang C, Shi H, Zhou J, Liang Y, Xu H.

Vaccine. 2009 Nov 5;27(47):6558-63. doi: 10.1016/j.vaccine.2009.08.047. Epub 2009 Sep 1.

PMID:
19729087
9.
10.

Thousand litre scale microcarrier culture of Vero cells for killed polio virus vaccine. Promising results.

Montagnon B, Vincent-Falquet JC, Fanget B.

Dev Biol Stand. 1983;55:37-42.

PMID:
6677539
11.

Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines.

Hu AY, Weng TC, Tseng YF, Chen YS, Wu CH, Hsiao S, Chou AH, Chao HJ, Gu A, Wu SC, Chong P, Lee MS.

Vaccine. 2008 Oct 23;26(45):5736-40. doi: 10.1016/j.vaccine.2008.08.015. Epub 2008 Aug 30.

PMID:
18761387
12.
13.

Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines.

Ramsay ME, Begg NT, Gandhi J, Brown D.

Pediatr Infect Dis J. 1994 Dec;13(12):1117-21.

PMID:
7892081
14.

Development of inactivated poliovirus vaccine derived from Sabin strains.

Simizu B, Abe S, Yamamoto H, Tano Y, Ota Y, Miyazawa M, Horie H, Satoh K, Wakabayashi K.

Biologicals. 2006 Jun;34(2):151-4. Epub 2006 May 5.

PMID:
16679028
15.

A new large-scale manufacturing platform for complex biopharmaceuticals.

Vogel JH, Nguyen H, Giovannini R, Ignowski J, Garger S, Salgotra A, Tom J.

Biotechnol Bioeng. 2012 Dec;109(12):3049-58. doi: 10.1002/bit.24578. Epub 2012 Jun 20.

PMID:
22688835
16.

Technology transfer of Sabin-IPV to new developing country markets.

Kreeftenberg H, van der Velden T, Kersten G, van der Heuvel N, de Bruijn M.

Biologicals. 2006 Jun;34(2):155-8. Epub 2006 May 2.

PMID:
16650773
17.

Trypsin diminishes the rat potency of polio serotype 3.

ten Have R, Westdijk J, Levels LM, Koedam P, de Haan A, Hamzink MR, Metz B, Kersten GF.

Biologicals. 2015 Nov;43(6):474-8. doi: 10.1016/j.biologicals.2015.07.010. Epub 2015 Aug 25.

PMID:
26321654
18.

Production, testing and perspectives of IPV and IPV combination vaccines: GSK biologicals' view.

Duchêne M.

Biologicals. 2006 Jun;34(2):163-6. Epub 2006 May 8.

PMID:
16682218
19.
20.

Inactivated poliovirus vaccine: current production methods and new developments.

van Wezel AL, van Steenis G, van der Marel P, Osterhaus AD.

Rev Infect Dis. 1984 May-Jun;6 Suppl 2:S335-40.

PMID:
6429814

Supplemental Content

Support Center